Pediatric Advisory Committee Will Preview CDK & PD-1 Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Pediatric subcommittee of the Oncologic Drugs Advisory Committee will discuss pediatric development plans for Novartis’ CDK inhibitor LEE011 and two immune checkpoint inhibitors, Bristol’s nivolumab and Merck’s MK-3475.